Cullgen develops targeted protein degraders using proprietary E3 ligands to address diseases that currently lack effective therapies, such as certain cancers. Their technology enables the degradation of previously undruggable proteins, offering a new approach to drug discovery and development.
Funding
$116M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ACFounders
Product
Problem
Many diseases, including certain cancers, lack effective therapies because the proteins that drive them are considered "undruggable" by traditional methods. These proteins lack binding sites for conventional drugs, making them difficult to target and inhibit.
Solution
Cullgen develops targeted protein degraders that leverage the ubiquitin-proteasome system (UPS) to eliminate disease-causing proteins. Their uSMITE™ platform utilizes novel E3 ligases to selectively tag target proteins for degradation, even those previously considered undruggable. This approach offers a new therapeutic modality for diseases where traditional drug discovery methods have failed, with an initial focus on developing treatments for various cancers. By harnessing the body's natural protein disposal mechanisms, Cullgen aims to create more effective and targeted therapies.
Target Audience
The primary target audience includes patients suffering from diseases, particularly cancers, that currently lack effective treatment options, as well as pharmaceutical companies seeking innovative drug development platforms.
Features
- uSMITE™ platform: A proprietary technology featuring novel E3 ligases for targeted protein degradation.
- Selective protein degradation: Targets and eliminates specific disease-causing proteins.
- Addresses "undruggable" targets: Enables the development of therapies for proteins that are not amenable to traditional drug discovery approaches.
- Potential for broad therapeutic applications: Applicable to a range of diseases, including cancer.